A gene expression-based immune signature for lung adenocarcinoma prognosis
- 5 May 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (9) , 1881-1890
Abstract
Background Lung adenocarcinoma (LUAD) has become the most frequent histologic type of lung cancer in the past several decades. Recent successes with immune checkpoint blockade therapy have demonstrated that the manipulation of the immune system is a very potent treatment for LUAD. This study aims to explore the role of immune-related genes in the development of LUAD and establish a signature that can predict overall survival for LUAD patients. Methods To identify the differential expression genes (DEGs) between normal and tumor tissues, we developed an analysis strategy to combine an independent-sample design and a paired-sample design using RNA-seq transcriptomic profiling data of The Cancer Genome Atlas LUAD samples. Further, we selected prognostic markers from DEGs and evaluated their prognostic value in a prediction model. Results We identified and validated PD1, PDL1 and CTLA4 genes as prognostic markers, which are well-known immune checkpoints, and revealed two new potential prognostic immune checkpoints for LUAD, HHLA2 (logFC = 2.55, FDR = 1.89 × 10–6) and VTCN1 (logFC = −2.86, FDR = 1.72 × 10–11). Furthermore, we identified an 18-gene LUAD prognostic biomarker panel and observed that the classified high-risk group presented a significantly shorter overall survival time (HR = 3.57, p value = 4.07 × 10–10). The prediction model was validated in five independent high-throughput gene expression datasets. Conclusions The identified DEG features may serve as potential biomarkers for prognosis prediction of LUAD patients and immunotherapy. Based on that assumption, we identified a gene expression-based immune signature for lung adenocarcinoma prognosis.Keywords
This publication has 44 references indexed in Scilit:
- Regulatory networks defining EMT during cancer initiation and progressionNature Reviews Cancer, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Increase of Circulating B7-H4–Expressing CD68+ Macrophage Correlated With Clinical Stage of Lung CarcinomasJournal of Immunotherapy, 2012
- Comparison of Pathway Analysis Approaches Using Lung Cancer GWAS Data SetsPLOS ONE, 2012
- IGF2BP1 promotes cell migration by regulating MK5 and PTEN signalingGenes & Development, 2012
- Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune SystemClinical Cancer Research, 2011
- Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non–Small Cell Lung Cancer from Patients with Nonmalignant Lung DiseaseCancer Research, 2009
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- A cytokine-mediated link between innate immunity, inflammation, and cancerJournal of Clinical Investigation, 2007
- Inflammation and cancerNature, 2002